{
    "SPADE_N_13744": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_N_13744",
            "Peptide Name": "Brevibacillin I (Bre I; natural AMPs; nonribosomal peptide, XXL; lipopeptide; XXw1; bacteria, prokaryotes)",
            "Source": "Brevibacillus laterosporusDSM 25",
            "Family": "Not found",
            "Gene": "Not found",
            "Sequence": "TLKIIVKIVKYLV",
            "Sequence Length": 13,
            "UniProt Entry": "Ref",
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anti-MRSA",
                "Hemolytic"
            ],
            "Target Organism": "Not found",
            "Hemolytic Activity": "Not found",
            "Cytotoxicity": "Not found",
            "Binding Target": "Not found",
            "Linear/Cyclic": "Not found",
            "N-terminal Modification": "Not found",
            "C-terminal Modification": "Not found",
            "Stereochemistry": "Not found",
            "Structure Description": "Not found",
            "Formula": "Not found",
            "Mass": 1529.99,
            "PI": 10.0,
            "Hydrophobicity": 1.54,
            "Half Life": "Not found",
            "Function": "Not found",
            "Literature": [
                {
                    "Author": "Zhao X, Wang X, Shukla R, Kumar R, Weingarth M, Breukink E, Kuipers OP.2021",
                    "Reference": "Front Microbiol. 2021 Jun 17;12:693725. doi: 10.3389/fmicb.2021.693725.PubMed",
                    "Title": "Brevibacillin 2V, a Novel Antimicrobial Lipopeptide With an Exceptionally Low Hemolytic Activity."
                }
            ],
            "Frequent Amino Acids": "IKV",
            "Absent Amino Acids": "ACDEFGHMNOPQRSUW",
            "Basic Residues": 3,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 9,
            "Polar Residues": 8,
            "Positive Residues": 3,
            "Negative Residues": 0,
            "Net Charge": 3,
            "Comments": "APD analysis reveals this sequence is most similar (92.31%) toBrevibacillinChemical modification: T1 dehydrated (Dhb); K3=Orithine, N-terminus is acylated with 2-hydroxy-3-methylvaleric acid (lipo); C-terminus is a characteristic valinol (an alcohol form of valine).Activity: Active against Gram+ S. aureus ATCC159750 or MRSA (MIC 2 ug/ml), E. faecium LMG16003 (VRE), E. faecalis LMG16216 (VRE), B. cereus ATCC14579 (MIC 2 ug/ml), Gram- A. baumannii ATCC17978 (MIC 64 ug/ml), E. coli ATCC25922 (MIC 32 ug/ml), P. aeruginosa LMG6395 (MIC 64 ug/ml), and K. pneumoniae LMG20218 (MIC 64 ug/ml).Toxicity: highly hemolytic: HC50=18.8 ug/ml and toxic: IC50 of HepG2 cells is 7.38 ug/ml.",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_13741",
                    "Similarity": 0.9230769230769231,
                    "Sequence": "TLKIIVKVVKYLV"
                },
                {
                    "SPADE_ID": "SPADE_N_07389",
                    "Similarity": 0.9,
                    "Sequence": "LIIVKIVKYL"
                },
                {
                    "SPADE_ID": "SPADE_N_15007",
                    "Similarity": 0.9,
                    "Sequence": "LIIVKIVKYL"
                }
            ]
        }
    }
}